1148 related articles for article (PubMed ID: 21388048)
21. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
22. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
Nagelkerke A; van Kuijk SJ; Sweep FC; Nagtegaal ID; Hoogerbrugge N; Martens JW; Timmermans MA; van Laarhoven HW; Bussink J; Span PN
Radiother Oncol; 2011 Oct; 101(1):39-45. PubMed ID: 21840613
[TBL] [Abstract][Full Text] [Related]
23. Beyond triple-negative breast cancer: the need to define new subtypes.
Constantinidou A; Jones RL; Reis-Filho JS
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307
[TBL] [Abstract][Full Text] [Related]
24. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
[TBL] [Abstract][Full Text] [Related]
25. Updates in the treatment of basal/triple-negative breast cancer.
Shastry M; Yardley DA
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
[TBL] [Abstract][Full Text] [Related]
26. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
27. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA; Elsheikh SE; Aleskandarany MA; Habashi HO; Green AR; Powe DG; El-Sayed ME; Benhasouna A; Brunet JS; Akslen LA; Evans AJ; Blamey R; Reis-Filho JS; Foulkes WD; Ellis IO
Clin Cancer Res; 2009 Apr; 15(7):2302-10. PubMed ID: 19318481
[TBL] [Abstract][Full Text] [Related]
29. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
30. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
31. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
32. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
Liu N; Wang X; Sheng X
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
[TBL] [Abstract][Full Text] [Related]
33. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
35. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
36. What is the difference between triple-negative and basal breast cancers?
Seal MD; Chia SK
Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
[TBL] [Abstract][Full Text] [Related]
37. Triple negative breast cancers: clinical and prognostic implications.
Dawson SJ; Provenzano E; Caldas C
Eur J Cancer; 2009 Sep; 45 Suppl 1():27-40. PubMed ID: 19775602
[TBL] [Abstract][Full Text] [Related]
38. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
39. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
40. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
